Cargando…

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future

γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen presentation, which makes them a highly promising effector cell compartment for cancer immunotherapy. Novel γδ T-cell-based immunotherapies, primarily focusing on the two major γδ T-cell subtypes that infiltrate tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saura-Esteller, José, de Jong, Milon, King, Lisa A., Ensing, Erik, Winograd, Benjamin, de Gruijl, Tanja D., Parren, Paul W. H. I., van der Vliet, Hans J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245381/ https://www.ncbi.nlm.nih.gov/pubmed/35784326 http://dx.doi.org/10.3389/fimmu.2022.915837

Ejemplares similares

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
por: Veluchamy, John P., et al.
Publicado: (2017)

P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES
por: Broijl, A., et al.
Publicado: (2022)

A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
por: Lameris, Roeland, et al.
Publicado: (2023)

Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
por: Fisher, Jonathan, et al.
Publicado: (2014)

Contemplating Dichotomous Nature of Gamma Delta T Cells for Immunotherapy
por: Bhat, Jaydeep, et al.
Publicado: (2022)

Combining radiotherapy with immunotherapy: the past, the present and the future
por: Van Limbergen, Evert J, et al.
Publicado: (2017)

Targeting gamma delta T cells for cancer immunotherapy: bench to bedside
por: Gogoi, Dimpu, et al.
Publicado: (2013)

Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy
por: Fisher, Jonathan, et al.
Publicado: (2018)

Allergen Immunotherapy: Past, Present, and Future
por: Jutel, Marek, et al.
Publicado: (2016)

Allergen immunotherapy: past, present and future
por: Durham, Stephen R., et al.
Publicado: (2022)

Immunotherapy With Human Gamma Delta T Cells—Synergistic Potential of Epigenetic Drugs?
por: Bhat, Jaydeep, et al.
Publicado: (2018)

Sarcoma Immunotherapy: Past Approaches and Future Directions
por: D'Angelo, S. P., et al.
Publicado: (2014)

Immunotherapy for Alzheimer’s disease: past, present and future
por: Spencer, Brian, et al.
Publicado: (2014)

Immunotherapy in hematologic malignancies: past, present, and future
por: Im, Annie, et al.
Publicado: (2017)

Past, Current, and Future of Immunotherapies for Prostate Cancer
por: Boettcher, Adeline N., et al.
Publicado: (2019)

Past, present, and future of allergen immunotherapy vaccines
por: Dorofeeva, Yulia, et al.
Publicado: (2020)

Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
por: Van Acker, Heleen H, et al.
Publicado: (2015)

Mathematical and numerical methods for the nonlinear hyperbolic propagation problem delta$^{2}$GAMMA/delta.t$^{2}$ = (delta/delta.z)((delta.GAMMA(delta.t)(delta.GAMMA/delta.z)): a preliminary treatment of collective space
por: Funk, U N, et al.
Publicado: (1982)

Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions
por: Ge, Lisheng, et al.
Publicado: (2010)

Cancer immunotherapy in clinical practice—the past, present, and future
por: Goel, Gaurav, et al.
Publicado: (2014)

Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”
por: D'Angelo, S. P., et al.
Publicado: (2015)

IL-21 in cancer immunotherapy: At the right place at the right time
por: Santegoets, Saskia JAM, et al.
Publicado: (2013)

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours
por: Nicol, A J, et al.
Publicado: (2011)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

A measurement of $\Delta \Gamma_{s}$
por: Aaij, Roel, et al.
Publicado: (2023)

Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
por: Stolk, Dorian, et al.
Publicado: (2018)

Current experimental status of $ \Delta \Gamma$ and $ \Delta m$
por: Schiller, Manuel Tobias
Publicado: (2018)

Exploitation of gamma delta T cells in cancer immunotherapy as combined antigen-presenters and cancer cell killers
por: Holmen Olofsson, Gitte, et al.
Publicado: (2014)

Immunotherapy in non‐small cell lung cancer: The past, the present, and the future
por: Lu, Meng, et al.
Publicado: (2019)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)

Host-directed immunotherapy of viral and bacterial infections: past, present and future
por: Wallis, Robert S., et al.
Publicado: (2022)

Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress
por: Chergui, Adel, et al.
Publicado: (2023)

Measurements of $\Delta m_{d,s}$ and $\Delta\Gamma_d$ at LHCb
por: Vecchi, Stefania
Publicado: (2017)

Measurements of $\Delta m_{d,s}$ and $\Delta \Gamma_d$ at LHCb
por: Vecchi, Stefania
Publicado: (2016)

LHC Perspectives for b lifetimes, $\Delta m, \Delta\Gamma$
por: Robbe, Patrick
Publicado: (2008)

Pancreatic Cancer and Immunotherapy: A Clinical Overview
por: Timmer, Florentine E. F., et al.
Publicado: (2021)

Studies $\Delta\Gamma_{s}/\Gamma_{s}$ and $sin 2\beta$ in ALEPH
por: Spagnolo, P
Publicado: (2000)

Measurement of $\phi_s$ and $\Delta\Gamma_s$ at LHCb
por: Batozskaya, Varvara
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rklqaemfo8apkvipmng55j5ek0